CGBIO's "DCLASSY PDRN" Receives IND Approval from Ministry of Food and Drug Safety

CGBIO announced on April 17 that its polynucleotide (PDRN)-based skin booster, "DCLASSY PDRN," has received Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety and will begin clinical trials to secure an indication for improving wrinkles around the eyes.

원본보기 아이콘

This clinical trial is scheduled to begin at the end of May this year and will target a total of 366 adult men and women aged between 19 and 65. The trial will involve administering DCLASSY PDRN to the wrinkles on both sides of the eyes and evaluating its safety and efficacy.

DCLASSY PDRN is a next-generation PDRN skin booster developed by CGBIO, focusing on resolving issues previously identified with existing PDRN products such as injection pain, immediate post-procedure embossing, and concerns about nodules.

Designed with high-purity, low-viscosity PDRN, it enables smoother injection and even distribution within the skin, while reducing the burden of returning to daily activities immediately after the procedure. The company expects that DCLASSY PDRN will be suitable not only for delicate and sensitive areas like the skin around the eyes but also for patients requiring repeated treatments.

Following the launch of its CaHA-based collagen booster "DCLASSY CaHA" last year, CGBIO is strengthening its skin booster lineup by adding this PDRN product to its portfolio. Through this effort, the company aims to enhance its competitiveness as a provider of customized solutions in the aesthetics market.

Hyun Seung Yoo, CEO of CGBIO, stated, "DCLASSY PDRN is a next-generation skin booster designed to maximize skin regeneration effects while minimizing pain and discomfort after the procedure. Through this clinical trial, we intend to prove its safety and efficacy, and we plan to pursue both domestic and global market launches, targeting a release in 2027."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.